Protocol Ledger

NCT07441642 · Phase II · RECRUITING

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventional Phase II clinical trial protocol NCT07441642 sponsored by Novartis in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-09 Enrollment: 272 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07441642
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)272 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07441642
Protocol FieldVerified Registry Value
NCT IdentifierNCT07441642
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment272 participants (ESTIMATED)
Registered Start Date2026-03-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07441642
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI